Use of 64Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: Molecular imaging

Radiology

Volumn 263, Issue 1, 2012, Pages 179-188

  Hackel, Benjamin J ^a   Kimura, Richard H ^a   Gambhir, Sanjiv S ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER EPIDERMAL GROWTH FACTOR RECEPTOR BINDING FIBRONECTIN DOMAIN E13.4.3' CU 64; EPIDERMAL GROWTH FACTOR RECEPTOR; RADIOPHARMACEUTICAL AGENT; TETRAXETAN; UNCLASSIFIED DRUG; COPPER; DIAGNOSTIC AGENT; FIBRONECTIN; MONOCLONAL ANTIBODY;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; GENE OVEREXPRESSION; HUMAN; IMAGE ANALYSIS; IN VITRO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN TARGETING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR LOCALIZATION; TUMOR XENOGRAFT; ANIMAL; CARCINOMA; CHEMISTRY; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; MICRO-COMPUTED TOMOGRAPHY; NONPARAMETRIC TEST; NUDE MOUSE; OVARY TUMOR; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIOGRAPHY; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COPPER RADIOISOTOPES; DRUG STABILITY; FEMALE; FIBRONECTINS; FLOW CYTOMETRY; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RECEPTOR, EPIDERMAL GROWTH FACTOR; STATISTICS, NONPARAMETRIC; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; X-RAY MICROTOMOGRAPHY;

EID: 84861309970     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12111504     Document Type: Article

References (42)

1. 64Cu labeled affibody protein. Bioconjug Chem 2010;21(5):947-954.
2. Nordberg E, Orlova A, Friedman M, et al. In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncol Rep 2008;19(4):853-857. (Pubitemid 351802651)
3. Tolmachev V, Rosik D, Wållberg H, et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 2010;37(3):613-622.
4. Zahnd C, Kawe M, Stumpp MT, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010;70(4):1595-1605.
5. Jiang L, Kimura RH, Miao Z, et al. Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin. J Nucl Med 2010;51(2):251-258.
6. Kimura RH, Cheng Z, Gambhir SS, Cochran JR. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res 2009;69(6):2435-2442.
7. 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med 2008;49(5):788-795.
8. 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 2008;10(3):167-175.
9. 3-integrin expression. J Nucl Med 2004;45(10):1776-1783.
10. 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007;34(6):850-858.
11. Niu G, Li Z, Xie J, Le Q-T, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 2009;50(7):1116-1123.
12. Niu G, Sun X, Cao Q, et al. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res 2010;16(7):2095-2105.
13. 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm 2008;23(2):158-171.
14. Sundaresan G, Yazaki PJ, Shively JE, et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44(12):1962-1969. (Pubitemid 40022142)
15. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55(17):3752-3756.
16. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009;8(10):2861-2871.
17. Hackel BJ, Ackerman ME, Howland SW, Wittrup KD. Stability and CDR composition biases enrich binder functionality landscapes. J Mol Biol 2010;401(1):84-96.
18. Koide A, Koide S. Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol Biol 2007;352:95-109.
19. Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel 2011;24(1-2):3-9.
20. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63(20):6962-6970. (Pubitemid 37322983)
21. Nieto Y, Nawaz F, Jones RB, Shpall EJ, Nawaz S. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol 2007;25(28):4405-4413. (Pubitemid 350013846)
22. Zlobec I, Vuong T, Hayashi S, et al. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer 2007;96(5):793-800. (Pubitemid 46376624)
23. Galizia G, Lieto E, Orditura M, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007;31(7):1458-1468. (Pubitemid 46945355)
24. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 2004;91(2):208-212. (Pubitemid 39037060)
25. Schlomm T, Kirstein P, Iwers L, et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 2007;13(22 pt 1):6579-6584. (Pubitemid 350206791)
26. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(suppl 4):S9-S15. (Pubitemid 32938124)
27. Memon AA, Jakobsen S, Dagnaes-Hansen F, Sorensen BS, Keiding S, Nexo E. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res 2009;69(3):873-878.
28. Zhang MR, Kumata K, Hatori A, et al. [11C]Gefitinib ([11c]Iressa): radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma. Mol Imaging Biol 2010;12(2):181-191.
29. 11C-labeled-4-N-(3- bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression. Cancer Sci 2007;98(9):1413-1416.
30. Kareem H, Sandström K, Elia R, et al. Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF. Tumour Biol 2010;31(2):79-87.
31. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003;2(3):131-137.
32. Antunes P, Ginj M, Walter MA, Chen J, Reubi J-C, Maecke HR. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue. Bioconjug Chem 2007;18(1):84-92. (Pubitemid 46145997)
33. García Garayoa E, Schweinsberg C, Maes V, et al. Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core. Bioconjug Chem 2008;19(12):2409-2416.
34. Cassady JR. Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys 1995;31(5):1249-1256.
35. 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol 2010;12(3):316-324.
36. Cheng Z, De Jesus OP, Namavari M, et al. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 2008;49(5):804-813. (Pubitemid 351717547)
37. Tolmachev V, Friedman M, Sandström M, et al. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med 2009;50(2):274-283.
38. Ahlgren S, Orlova A, Rosik D, et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug Chem 2008;19(1):235-243. (Pubitemid 351213855)
39. 111In-benzyl- DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 2006;47(5):846-853.
40. 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009;50(3):417-425.
41. Kramer-Marek G, Kiesewetter DO, Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med 2009;50(7):1131-1139.
42. Behr TM, Sharkey RM, Juweid ME, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55(17):3825-3834.